Mylan To Appeal Lorazepam, Clorazepate Antitrust Decision Awarding $35.9 Million In Damages
This article was originally published in The Pink Sheet Daily
In the last of pending antitrust cases related to lorazepam and clorazepate monopoly, D.C. district court orders Mylan to pay $35.9 million to health insurers.
You may also be interested in...
The virtual J.P. Morgan Healthcare meeting was missing the usual energy but still had substance.
US vaccination campaign will pick up speed now that access is broadening, leaders from Operation Warp Speed, Pfizer, Moderna, McKesson and CVS Health say at a J.P. Morgan panel discussion.
Vir believes its single antibody will be effective against rising mutant forms of COVID-19. Phase III data from two ongoing trials are expected in the first quarter.